key: cord-1022832-d0vt8mba
authors: Muhammad, Ijaz; Rahman, Noor; Gul-e-Nayab; Niaz, Sadaf; Basharat, Zarrin; Rastrelli, Luca; Jayanthi, Sivaraman; Efferth, Thomas; Khan, Haroon
title: Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants
date: 2021-04-16
journal: Comput Biol Med
DOI: 10.1016/j.compbiomed.2021.104362
sha: dd68f84a8fbd8b762486b16e8df40f56aba8e777
doc_id: 1022832
cord_uid: d0vt8mba

BACKGROUND: COVID-19, declared a pandemic in March 2020 by the World Health Organization is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The virus has already killed more than 2.3 million people worldwide. OBJECT: The principal intent of this work was to investigate lead compounds by screening natural product library (NPASS) for possible treatment of COVID-19. METHODS: Pharmacophore features were used to screen a large database to get a small dataset for structure-based virtual screening of natural product compounds. In the structure-based screening, molecular docking was performed to find a potent inhibitor molecule against the main protease (M(pro)) of SARS-CoV-2 (PDB ID: 6Y7M). The predicted lead compound was further subjected to Molecular Dynamics (MD) simulation to check the stability of the leads compound with the evolution of time. RESULTS: In pharmacophore-based virtual screening, 2,361 compounds were retained out of 30,927. In the structure-based screening, the lead compounds were filtered based on their docking scores. Among the 2,360 compounds, 12 lead compounds were selected based on their docking score. Kazinol T with NPASS ID: NPC474104 showed the highest docking score of -14.355 and passed criteria of Lipinski’s drug-like parameters. Monitoring ADMET properties, Kazinol T showed its safety for consumption. Docking of Kazinol T with two Asian mutants (R60C and I152V) showed variations in binding and energy parameters. Normal mode analysis for ligand-bound and unbound form of protease along with its mutants, revealed displacement and correlation parameters for C-alpha atoms. MD simulation results showed that all ligand-protein complexes remained intact and stable in a dynamic environment with negative Gibbs free energy. CONCLUSIONS: The natural product Kazinol T was a predicted lead compound against the main protease of SARS-CoV-2 and will be the possible treatment for COVID-19.

Tyrrell and colleagues studied several animal viruses using electron microscopy in the 1960s, including infectious bronchitis virus, mouse hepatitis virus and transmissible gastroenteritis virus of swine. These viruses revealed a similar morphology (McIntosh et al., 1967; Witte and Tajima 1968 ) and were clustered together as a new virus group. This new set of viruses was termed as 'coronaviruses' (corona denoting the crown-like appearance of the surface projections) and was officially accepted as a new genus of viruses (Tyrrell et al., 1975) .

These viruses have a large variety and previously caused several outbreaks. In 2002 modified strain of coronavirus emerged from southern China, caused severe acute respiratory syndrome (SARS) and spread throughout the world with quantifiable speed (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003) . In Wuhan, the capital city of Hubei province of China, pneumonia cases of unknown origin were identified in early December 2019 . The responsible pathogen was identified as a novel enveloped RNA β-coronavirus . It is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is phylogenetically similar to SARS-CoV (Zhu et al., 2019) . In recent studies, the severity of some cases of COVID-19 imitated that of SARS-CoV (Huang et al., 2020; Chen et al., 2020) .

WHO declared the coronavirus disease 2019 (COVID-19) as a public health emergency of international concern on 30 th January 2020 (https://www.who.int). According to WHO statistics, there were more than 106 million COVID-19 cases and more than 2.3 million deaths globally from the disease (dated: February 8, 2021;

https://www.worldometers.info/coronavirus/). It affected >210 countries and territories around the world. So far, the percentage of severe cases remains high, calling for effective regimes for this highly contagious disease (Lai et al., 2002; Xiang et al., 2020) . Scientists are striving hard to find specific antiviral drugs. Numerous drugs such as chloroquine, arbidol, remdesivir, and favipiravir were in clinical trials to treat COVID-19, but none provided convincing evidence of safety and efficacy .

Therefore, an effective drug against SARS-CoV-2 still needs to be discovered. In the present study, we aimed to evaluate natural product compounds for the inhibition of the main protease of SARS-CoV-2. The comparative binding was also carried out with Asian mutants of M pro recently reported by Cross et al. (2020) . We believe that our findings will help pharmaceutical chemists to optimize suitable drugs for the clinical management of COVID-19 patients.

The co-crystallized structure of the main protease (ID: 6Y7M) of SARS- J o u r n a l P r e -p r o o f

In a molecular docking approach, the pharmacophore-based screened library (2361 compounds) was docked with the three-dimensional structure of the target protein. The protein structure of native and mutant M pro was prepared in MOE for docking. The 3D protonation and energy minimization of the protein as well as site finder was used to predict the active site residues of the binding pocket . 

The compound with the best molecular docking results to the viral protein was considered for Molecular Dynamics simulation, in order to understand the interaction and stability of the protein-ligand complex. Maestro-Desmond Interoperability Tools (Schrödinger, New York, NY, 2020) system builder was used for the purpose. The explicit water solvation TIP3P model was used with orthorhombic box shape (size deliberated by box size calculation J o u r n a l P r e -p r o o f method) of absolute size with a volume of 412556 Å 3 . The OPLS3e force field was used to rectify the geometries. The system was then minimized using a maximum of 1000 iterations with a convergence threshold of 1.0 kcal/mol Å 3 . The in silico simulation of the system was carried out for an interval of 100 ns and with a recording interval of an energy equivalent to 5 and a trajectory of 4.8. The NPT ensemble corresponded to a temperature of 300 K and a pressure of 1.01325 bar (Desmond Molecular Dynamics System, NY, 2020).

Strong medical support and self-isolation can enhance the cure rate, reduce the mortality rate of infected individuals, and the spread of SARS-CoV-2 (Cheng and Shan, 2019; . Still, thousands of severely ill patients are dying every day. The guidelines issued by WHO and National Health Commission for diagnosis and treatment of SARS-CoV-2 suggest that ribavirin, lopinavir/ritonavir antiviral therapy may be used to treat SARS-CoV-2 patients (Wu et al., 2020) , but a permanent and efficient cure is still urgently required. Natural products may be useful in discovering novel therapeutics to ease the current COVID-19

pandemic (Verma et al 2020) . The main protease (PDB ID: 6Y7M) is a key protein in the SARS-CoV-2 life cycle. This enzyme cuts the poly-proteins translated from viral RNA to yield functional viral proteins. The first crystal structure of SARS-CoV main protease and its complex with a hexapeptidyl chloromethylketone (CMK) inhibitor has been previously reported (Yang et al., 2003) . The three-dimensional structure of the protein is shown in Fig.   1 . L-canavanine from Sutherlandia frutescens has been described as potential inhibitor of the SARS-CoV-2 3C-like main protease using informatics based approaches (Dwarka et al., 2020 ).

In the present study, the active site of the protein was predicted prior to docking analyses for attaining best docking results. The pocket residues of the protease protein (PDB ID: 6Y7M) were 3CL pro with IC 50 values of 8.9 ± 0.5 μg/ml and 8.8 ± 0.5 μg/ml, respectively. Thearubigin, the polymeric phenol, bound to the CYS145 residue of the active site of the protease and might serve as pharmaco-active molecule.

After virtual screening of 30,927 compounds based on pharmacophoric features of the cocrystalized ligand (such as an anionic and cationic atom, H-bond donor and acceptor, aromatic centre, Pi-ring centre and hydrophobic centroid), the dataset was reduced to 2,361 compounds. These compounds were docked to the SARS-COV-2 protease. Twelve compounds derived from various natural sources (e.g. fungi, plants, and microbes) showed docking scores below -12 (Table 1 ). In addition, 18 compounds revealed higher docking score values than the positive control (OEW, docking score -11.5448). However, a cut-off value of -12 was considered in this study. The chemical structures of the compounds with the highest docking scores along with the standard compound (control) are shown in Table 1 .

Kanjanasirirat et al, 2020 tested 122 Thai natural products and found panduratin A from (Fig. 3b) .

Met165 formed moderate interactions with ebenfuran III, which may be useful for drug development against M pro . Ebenfuran III may serve as lead molecule to design and synthesize benzofuran derivatives substituted directly at C-2 with different heterocyclic groups. The pentene ring of NPC476350 (ebenfuran III) formed an arene-hydrogen interaction with

Met165 and Asn142 and bound to the hydroxyl group of the ligand by the side-chain donor (acidic) (Fig. 3c) . Generally, the addition of an isoprenoid chain rendered the derivate pharmacologically more effective than the parent compound, probably because the prenyl group increased the lipophilicity and conferred a strong affinity for biological membranes.

Here, the prenyl moiety at position C-5, rather than the formyl group at C-3, was the key determinant of the activity of ebenfuran III. The hydroxyl group of NPC472630 (paulownione A) isolated from Paulownia tomentosa contains a benzene ring. This ring bound to Ser144 by a side-chain donor (acidic) interaction and another hydroxyl group to Gln189 by a backbone donor (greasy) interaction to the receptor protein (Fig. 3d) Table 3 . The inhibition analysis showed various binding affinities for the mutants R60C and I152V, with decreased S-values of -5.9 and -7.09, respectively (Fig. 5) . The native protease formed 13 interactions (Fig. 3a) , while R60C made 9 common and four new interactions (Thr25, Thr26, Cys44, Thr45). I152V revealed 8 common and six new interactions (Phe140, Leu141, Tyr54, Glu166, Val186, Arg188) compared to the native protease.

Previously, andrographolide from Andrographis paniculata has been identified in silico as a potential inhibitor of the SARS-COV-2 main protease (M pro ) by molecular docking analysis, toxicity and ADME predictions (Enmozhi et al, 2020) . We conducted an ADMET analysis of NPC474104 (kazinol T; molecular weight: 480.29 g/ml), which scored the highest inhibition J o u r n a l P r e -p r o o f against protease of SARS-CoV-2. A logP value of 6.03, five hydrogen bond acceptors, four hydrogen bond donors and 9 rotatable bonds were obtained. It showed high probability for intestinal absorption (0.99), passing the blood-brain barrier and the potential for inhibition of phase II enzymes (CYP3A4, CYP2C9, CYP2D6, CYP2C19 and CYP1A2) and phase III transporters BSEP, OATP1B1, OATP1B3, OATP2B1) . Kazinol T also bound to other receptors, e.g. receptors for estrogen, androgen, glucocorticoid, aromatase etc. The compound tested negative for hepatotoxicity, AMES mutagenesis and carcinogenicity.

Concerning ecotoxicology, it appeared as toxic against honey bees and fishes. The water solubility was -3.565 logS, while the plasma protein binding capability was 1.21%. Acute oral toxicity was recorded as LD 50 =2.825 mg/kg. The Swiss ADME server did not show a violation of the Lipinski's criteria for drug-likeliness and revealed a bioavailability score of 0.55. The synthetic accessibility was 4.87, while the skin permeation was -3.91 cm/s. The physicochemical space for oral bioavailability of this compound is shown in Fig. 6 .

Previously, Chen et al. (2005) reported tannic acid and 3-isotheaflavin-3-gallate as SARS-CoV-1 protease inhibitors by screening a natural product library consisting of 720 natural polyphenols from tea. Extracts from pure tea and black tea were also potent inhibitors of SARS-CoV-1 protease activity. We increased the size of the compound library and, hence, the chemical space against the protease of SARS-CoV-2. These compounds could serve as new drug leads for the treatment of viral diseases. Therefore, further research in this area is desirable. Kar et al. (2020) performed molecular dynamics simulation of the SARS-CoV-2 spike protein, RdRp and M pro with taraxerol. This compound exhibited better binding energy scores with the concerned viral proteins than the drugs that are specifically designed to target them.

MD simulations became an important computational tool for understanding the physical basis of the structure and function of biological macromolecules. MD simulations are comparable with an induced-fit model, as it can be used to assess stability, to refine and to rescore docking poses (Haberl et al., 2009; Salmaso and Moro, 2018) . MD simulation was run to monitor the atomic level interaction and stability of the best pose complexes of the main protease and its two mutants (R60C and I152V) with NPC474104 (kazinzol T). The best molecular docking-generated poses of the complexes were subjected to MD simulation by using the Desmond program. The system builder in Desmond uses clear aqueous medium followed by the energy minimization step to lower the energy of the system. The real-time simulation of 100 nanoseconds (ns) showed that the kazinol T-protease (wild-type and R60C

and I152V mutants) complexes were stable in a dynamic environment at 300 K temperature and 1.01325 bar pressure. H-bonding, hydrophobic interactions, ionic contact and water bridges supported the binding with the protein, resulting in a significant structural change in the viral protein, potentially leading to protein cleavage. In MD simulation, the stability of the protein-ligand complex is represented in terms of Root Mean Square Deviation (RMSD) (Kumar et al., 2015) . The RMSD plots of protein-ligand complexes of wild-type and its two Asian mutants of SARS-CoV-2 are shown in Fig. 7a, 7b , and 7c. The RMSD values of proteins and ligand were always on the same trajectory and did not show any deviation. The RMSD pattern averaged around 1.8 Å for the wild-type protease-kazinol T and mutant R60Ckazinol T complexes and 1.5 Å for the mutant I152V-kazinol T complex. The wild-type protease and mutant R60C showed the same RMSD pattern. However, the mutant I152V protease-kazinol T was not a stable complex from 0 to 25 ns, but formed a stable complex from 25 to 100 ns. The comparative protein backbone RMSD plot showed the stability of the protein backbone of the wild-type protease and its two mutants (R60C and I152V) (Fig. 8) .

The RMSD value varied around an average of 1.7Å. The comparative binding energies of the J o u r n a l P r e -p r o o f ligand-protein complexes from 0 to 100 ns were in a range of -30 kcal/mol to -75 kcal/mol for all complexes (Fig. 9) . These results reflected the stability of our predicted lead compound among the top complexes.

Computational docking methods are valuable tools aimed to facilitate the costly and timeconsuming process of drug development and improvement. Most current approaches assume a rigid receptor structure to allow virtual screening of large numbers of possible ligands and putative binding sites on a receptor molecule. However, it is not possible to mimic and simulate the biological system on a computer.

Natural products are easily available and can be usually extracted at low costs in large quantities. Still, it is a daunting job to narrow down pharmacologically useful compounds from the entire plethora of compounds. In the current study, we used a swift computational strategy to identify inhibitors of SARS-CoV-2 protease from a natural product database with a large number of compounds. Along with several other compounds, kazinol T (NPC474104) was identified as a potent inhibitor, showing a docking score of -14.355008 kcal/mol and no considerable toxicity predictions. MD simulations validated that these complexes were stable.

Further in vitro tests with cell lines and affinity optimization studies are needed to validate this predicted lead compound for the treatment of COVID-19. The newly identified small molecules against SARS-COV-2 protease may also serve as inhibitors for other similar viral proteases.

Tyrosinase inhibitory effects of 1, 3-diphenylpropanes from Broussonetia kazinoki

Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3, 3'-digallate (TF3). Evidence-Based Complementary and Alternative Medicine

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Sequence characterization and molecular modeling of clinically relevant variants of the SARS-CoV-2 main protease

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Identification of potential SARS-CoV-2 inhibitors from South African medicinal plant extracts using molecular modelling approaches

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): The epidemic and the challenges

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Growth in suckling-mouse brain of "IBV-like" viruses from patients with upper respiratory tract disease

Butyrolactone I derivatives from Aspergillus terreus carrying an unusual sulfate moiety

Coronavirus as a possible cause of severe acute respiratory syndrome

Virtual screening of natural products against Type II Transmembrane Serine Protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2)

Vaccine design from the ensemble of surface glycoprotein epitopes of SARS-CoV-2: An immunoinformatics approach. Vaccines

Inhibitory effects of plant extracts and in silico screening of the bioacti e compounds against α-glucosidase

Pharmacoproteomic study of the natural product ebenfuran III in DU-145 prostate cancer cells: The quantitative and temporal interrogation of chemically induced cell death at the protein level

Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview

Evaluation of medicinal herbs as a potential therapeutic option against SARS-CoV-2 targeting its main protease

Anti-SARS-CoV natural products with the potential to inhibit SARS

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in

Morphologic characteristics and nucleic acid type of transmissible gastroenteritis virus of pigs. Archiv für die gesamte Virusforschung

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

Timely research papers about COVID-19 in China

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Clinical characteristics of 140 patients infected with SARS-CoV-2 in

Crystal structure of SARS-CoV-2 main protease provides a basis for design of impro ed α-ketoamide inhibitors

A novel coronavirus from patients with pneumonia in China

The authors declare that there is no conflict of interest.